Real‐world experience of nivolumab in the treatment of poor performance status patients with advanced non‐small cell lung cancer

BACKGROUND: Nivolumab improves disease control and survival in advanced NSCLC in patients with good performance status (PS), but there is limited data on its efficacy in patients with poor PS. AIM: Primary objective of the study was to evaluate the efficacy and safety of nivolumab and examine the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, M. Nazim, Klevansky, Myron, Koczwara, Bogda, Roy, Amitesh Chandra, Sukumaran, Shawgi, Vatandoust, Sina, Karapetis, Christos Stelios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955060/
https://www.ncbi.nlm.nih.gov/pubmed/34196124
http://dx.doi.org/10.1002/cnr2.1487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955060/
https://www.ncbi.nlm.nih.gov/pubmed/34196124
http://dx.doi.org/10.1002/cnr2.1487

Ejemplares similares